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ABSTRACT
Numerous clinical entities have now been identified to cause pathologic iron
accumulation in the liver. Some are well described and have a verified hereditary basis; in
others the genetic basis is still speculative, while in several cases nongenetic iron-loading
factors are apparent. The non-HFE hemochromatosis syndromes identifies a subgroup of
hereditary iron loading disorders that share with classic HFE-hemochromatosis, the
autosomal recessive trait, the pathogenic basis (i.e., lack of hepcidin synthesis or activity),
and key clinical features. Yet, they are caused by pathogenic mutations in other genes, such
as transferrin receptor 2 (TFR2), hepcidin (HAMP), hemojuvelin (HJV), and ferroportin
(FPN), and, unlike HFE-hemochromatosis, are not restricted to Caucasians. Ferroportin
disease, the most common non-HFE hereditary iron-loading disorder, is caused by a loss of
iron export function of FPN resulting in early and preferential iron accumulation in
Kupffer cells and macrophages with high ferritin levels and low-to-normal transferrin
saturation. This autosomal dominant disorder has milder expressivity than hemochroma-
tosis. Other much rarer genetic disorders are associated with hepatic iron load, but the
clinical picture is usually dominated by symptoms and signs due to failure of other organs
(e.g., anemia in atransferrinemia or neurologic defects in aceruloplasminemia). Finally, in
the context of various necro-inflammatory or disease processes (i.e., chronic viral or
metabolic liver diseases), regional or local iron accumulation may occur that aggravates
the clinical course of the underlying disease or limits efficacy of therapy.
KEYWORDS: Iron overload, non-HFE hemochromatosis, transferrin receptor 2,
hepcidin, ferroportin, hemojuvelin
The liver is the main source of the iron-regu-
latory hormone hepcidin and plays a central role in the
homeostatic control of iron traffic in the body. Although
intestinal iron absorption is tightly regulated to sustain
hemoglobin synthesis and critical cell functions, there is
no active mechanism for iron excretion from the body.1
This exposes humans to a substantial risk for iron over-
load and iron-driven toxicity, particularly in the liver, the
principal iron storage site in the body. Excess iron, in
solution with oxygen, may generate free radical formation
via Fenton and Haber-Weiss chemistry, with hydrogen
peroxide (H2O2), being changed into its noxious hy-
droxyl radical (HO). This leads to consequent damage to
DNA, proteins, and membranes.2 The classic example of
iron overload in human pathology is HFE-hereditary
hemochromatosis (HC), but numerous other entities are
now identified to cause pathologic iron accumulation in
the liver3 (Table 1). Some are well described and have a
verified hereditary basis, whereas in others the genetic
and hereditary basis is still speculative. A large percentage
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reflect systemic iron overload, others, in the context of a
necro-inflammatory, or in as yet unknown disease proc-
esses, results in regional or local iron accumulation (e.g.,
chronic liver diseases) (Table 1). Finally, an increasingly
recognized class of iron disorders is due to disrupted
intracellular (e.g., Friedreich ataxia) or body iron traffic
(e.g., anemia of chronic diseases) leading to iron misdis-
tribution despite a normal total body iron content
(Table 1). Here we will discuss causes and consequences
of most common hereditary or acquired disorders asso-
ciated with hepatic iron overload beyond HFE-hemo-
chromatosis.
HEREDITARY DISORDERS
Non-HFE Hereditary Hemochromatosis
Hemochromatosis, or hereditary hemochromatosis, has
been historically considered a unique clinicopathologic
entity likely due to a single gene defect. This view
seemed to be confirmed in 1996 when a single-gene
polymorphism was found in most hemochromatotic
patients worldwide4(see also Olynyk et al elsewhere in
this issue). However, as genetic testing for HFE became
more widespread and nearly one-fifth of HC patients
turned out to lack the pathogenic p.Cys282Tyr change,
it rapidly became clear that the situation was more
complicated than previously thought.5 Other iron genes
whose mutations were associated with hereditary iron
overload syndromes with some, or many, or apparently
even all of the phenotypic features of classic HC, were
reported: transferrin receptor 2 (TFR2),6 hepcidin
(HAMP),7 hemojuvelin (HJV),8 and ferroportin (FPN)
(Table 1).9,10
Today, the term non-HFE hereditary hemochro-
matosis embraces all forms of HC nonlinked to the
commonHFE p.Cys282Tyr polymorphism, and thus far
associated with pathogenic mutations of TFR2, HJV,
HAMP, and in rare cases, the FPN gene. These non-
HFE hemochromatosis syndromes share with classic
HFE-HC key features, namely (1) early and progressive
expansion of the plasma iron compartment (increasing
Table 1 Common Causes of Non-HFE Iron Overload or Mis-Distribution in Humans
Iron Overload Iron Mis-Distribution
Hereditary Hereditary
Disorder/Cause Pattern of Iron Accumulation Disorder/Cause Pattern of Iron Accumulation
Non-HFE hereditary hemochromatosis
(TFR2-, HJV-, HAMP-, FPN-related)
Systemic X-linked sideroblastic
anemias
Systemic (mitochondria)
Ferroportin disease (classic form) Systemic Fiedreich ataxia Systemic (mitochondria)
Aceruloplasminemia Systemic
Atransferrinemia Systemic
DMT-1 deficiency Regional (mainly liver)
H-ferritin related iron overload Systemic
Hereditary iron-loading anemias
with inefficient erythropoiesis
Systemic (early hepatic iron load
due to increased iron absorption)
Acquired Acquired
Disorder/Cause Pattern of Iron Accumulation Disorder/Cause Pattern of Iron Accumulation
Oral Systemic Anemia of chronic
diseases
Systemic (macrophages)
Parenteral Systemic
Posttransfusion Systemic (preferential iron
accumulation in macrophages)
Chronic liver diseases (viral- and
alcohol-related; NASH)
Regional (liver)
Neurodegenerative disorders Regional (brain)
Miscellaneous
Disorder/Cause Pattern of Iron Accumulation
Porphyria cutanea tarda Systemic (mainly liver)
African siderosis Systemic
Alloimmune (neonatal)
hemochromatosis
Systemic
TFR2, transferrin receptor-2; HAMP, hepcidin; HJV, hemojuvelin; FPN, ferroportin; NASH, nonalcoholic steatohepatitis.
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transferrin saturation [TS]), which precedes tissue iron
overload (increasing serum ferritin [SF]); (2) progressive
and preferential iron deposits in parenchymal cells with
potential for severe damage and disease that may involve
liver, endocrine glands, heart, and joints; (3) nonim-
paired erythropoiesis and optimal response to therapeu-
tic phlebotomy; and (4) inadequate hepcidin synthesis or
activity.3 These similarities with HFE-HC stem from
the fact that—beyond their genetic diversities—all
known hemochromatoses belong to the same clinicopa-
thologic entity, as they all originate from the failure to
prevent unneeded iron from entering the circulatory pool
due to hepcidin deficiency (see also, Babitt and Lin, this
issue; and below). Depending on the gene involved and
its role in hepcidin regulation, the phenotype of HC
varies, ranging from the severe HJV- and HAMP-juve-
nile forms, to the relatively milder adult-onset TFR2 and
FPN phenotypes.
EPIDEMIOLOGY
Unlike HFE, none of the non-HFE-HC genes appears
to be restricted to northern European descent. Most
cases of TFR2-HC represent largely inbred families of
Italian extraction with high consanguinity.11–15 How-
ever, pathogenic mutations of TFR2 have also been
identified in other ethnicities, including Asian popula-
tions.16–21 In Asians, where HFE-HC is almost non-
existent, TFR2-HC seems a common form of
hereditary HC. Reported TFR2 mutations include
missense and nonsense, deletions, and frameshifts,
followed by a premature stop codon and alternative
splicing mutations (Table 2).
Although most FPN mutations give rise to a
distinct form of hereditary iron overload called ferro-
portin disease72 (see below), unusual FPN mutations are
believed to cause rare forms of HC similar to HFE-
HC.28–31,33,35,36,38
Most cases of so-called juvenile HC (JHC) are
due to mutations of HJV, formerly HFE2.8 Many HJV
pathogenic mutations have been reported;42,54,55,57 one,
p.Gly320Val, seems more common than others as it has
been found in most reported pedigrees worldwide
(Table 2).8,34,42,43,46,47,51,58–61
The study of additional cases with JHC identified
a cohort demonstrating mutations in HAMP, the gene
encoding hepcidin, on chromosome 19q13.7HAMP-HC
is much rarer than HJV-HC, and only few cases have
been reported so far.34,64–66,69–71 The concept and spec-
trum of JHC has been further extended by the identi-
fication of patients with combined mutations for HFE
and TFR2 presenting with a severe hemochromatotic
syndrome identical to JHC.24
In addition, there is evidence that selected HJV
and HAMP mutations, when carried simultaneously
with mutant HFE, may aggravate and accelerate the
course of classic HC (Table 2).45,48,53,67,68
PATHOGENESIS
The first biochemical manifestation of all forms of
HC, regardless of the pathogenic gene involved, is an
increase of TS that reflects an uncontrolled influx of
iron into the bloodstream from enterocytes and mac-
rophages.73 As the body has no effective means of
significantly reducing plasma iron levels, without
therapeutic intervention, overload in the plasma com-
partment will lead to the progressive accumulation of
iron in the parenchymal cells of key organs, creating a
distinct risk for oxidative damage. The time of onset
and pattern of organ involvement in HC vary depend-
ing on the rate and magnitude of plasma iron over-
loading, which depends in turn on the underlying
genetic mutation. The latter determines the extent of
hepcidin deficiency and eventually the rate and mag-
nitude of body iron loading. For this reason, milder
adult-onset forms (e.g., TFR2- and FPN-related) and
more severe juvenile-onset forms (e.g., HJV- and
HAMP-related) of HC are recognized. Iron release
from enterocytes and macrophages into the blood-
stream in humans is under the control of the hepci-
din–ferroportin axis. It now seems that most non-
HFE HC genes play a role in conveying the iron
signal to hepcidin, although the details of this process
are not fully uncovered (see Babitt and Lin, this
issue). In the rare cases of FPN-HC, instead FPN
mutations are thought to impair hepcidin-triggered
FPN degradation and/or FPN internalization/degra-
dation (see De Domenico, Ward, and Kaplan, this
issue).74
CLINICAL ASPECTS
In view of the genetic and pathogenic considerations
expressed above, HC can be seen as a genetically
heterogeneous disease that results from the complex
interaction between genetic and acquired factors. If the
altered gene plays a dominant role in hepcidin syn-
thesis/activity (e.g., HAMP itself or HJV), circulatory
iron overload occurs rapidly and reaches high levels. In
these cases, the modifying effects of acquired environ-
mental and lifestyle factors will be negligible and the
clinical presentation will invariably be dramatic, with
early onset (first to second decade) of a full-blown
organ disease.3 In contrast, p.Cys282Tyr HFE homo-
zygosity results in a genetic predisposition that requires
the concurrence of host-related or environmental fac-
tors to produce disease (see also, Gan, Powell, and
Olynyk, this issue). As mentioned, co-inherited muta-
tions in other HC genes, such as HAMP and HJV, may
have a role in disease penetrance of HFE-HC, but they
are rare.45,48,53,67,68
The clinical appearance of TFR2-HC patients
mimics that of HFE-hereditary HC, namely patients
with high TS and SF and low penetrance in premeno-
pausal women.13 Age range is somewhat younger, but
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Table 2 Non-HFE Hemochromatosis: Reported Gene Mutations
Nucleotide
Change
Amino Acid
Change Type of Variation Phenotype References
TFR2 (RefSeq NM_003227.3, NP_003218.2)
1 c.64G>A p.Val22Ile Missense (heterozygous) Postulated effect
on iron status
22
2 c.88_89insC p.Arg30ProfsX31 Frameshift (homozygous) Hemochromatosis 12
3 c.313C>T p.Arg105X Nonsense (homozygous) Hemochromatosis 18
4 c.515T>A p.Met172Lys Missense (homozygous) Hemochromatosis 12,14
5 c.614þ 4A>G Splicing (homozygous) Hemochromatosis 23
6 c.750C>G p.Tyr250X Nonsense (homozygous) Hemochromatosis 6,11
7 c.949C>T p.Gln317X Nonsense (homozygous) Hemochromatosis 24
8 c.1186C>T p.Arg396X Nonsense (compound
heterozygous with
p.Gly792Arg or
c.1538–2A>G)
Hemochromatosis 15,20
9 c.1231_1233del3 p.Asn411del Deletion (compound
heterozygous with
p.Ala444Thr)
Hemochromatosis 25
10 c.1330G>A p.Ala444Thr Missense (compound
heterozygous with
p.Asn411del)
Hemochromatosis 25
11 c.1364G>A p.Arg455Gln Missense (heterozygous) Putative modifier in
p.Cys282Tyr
HFE homozygous
26
12 c.1403G>A p.Arg468His Missense (homozygous) Hemochromatosis 21
13 c.1469T>G p.Leu490Arg Missense (homozygous) Hemochromatosis 19
14 c.1538–2A>G Splicing (compound
heterozygous with p.Arg396X)
Hemochromatosis 15
15 c.1665delC p.Ser556AlafsX6 Frameshift (homozygous) Hemochromatosis 19
16 c.1861_1872del12 p.Ala621_Gln624del Deletion (homozygous) Hemochromatosis 13,17
17 c.2069A>C p.Gln690Pro Missense (homozygous) Hemochromatosis 16
18 c.2137–1G>A Splicing (homozygous) Hemochromatosis 25
19 c.2374G>A p.Gly792Arg Missense (compound
heterozygous
with p.Arg396X)
Hemochromatosis 20
SLC40A1 (RefSeq NM_014585.5, NP_055400.1)
1 c.-59_-45del15 Deletion (heterozygous) Hemochromatosis* 27
2 c.190T>A p.Tyr64Asn Missense (heterozygous) Hemochromatosis 28
3 c.430A>C p.Asn144His Missense (heterozygous) Hemochromatosis 29
4 c.430A>G p.Asn144Asp Missense (heterozygous) Hemochromatosis 30
5 c.431A>C p.Asn144Thr Missense (heterozygous) Hemochromatosis 31
6 c.718A>G p.Lys240Glu Missense (heterozygous) Hemochromatosis* 32
7 c.977G>A p.Cys326Tyr Missense (heterozygous) Hemochromatosis* 33,34
8 c.977G>C p.Cys326Ser Missense (heterozygous) Hemochromatosis 35
9 c.1014T>G p.Ser338Arg Missense (heterozygous) Hemochromatosis 36
10 c.1502A>G p.Tyr501Cys Missense (heterozygous) Hemochromatosis* 37
11 c.1520A>G p.His507Arg Missense (heterozygous) Hemochromatosis 38
HJV (RefSeq NM_213653.3, NP_998818.1)
1 c.81delG p.Leu28SerfsX24 Frameshift (homozygous) Juvenile hemochromatosis 39
2 c.160A>T p.Arg54X Nonsense (homozygous) Juvenile hemochromatosis 40
3 c.196G>T p.Gly66X Nonsense (homozygous) Juvenile hemochromatosis 41
NON-HFE HEPATIC IRON OVERLOAD/PIETRANGELO ET AL 305
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
itä
ts
bi
bl
io
th
ek
 In
ns
br
uc
k 
(U
BI
). C
op
yri
gh
ted
 m
ate
ria
l.
Table 2 (Continued )
Nucleotide
Change
Amino Acid
Change Type of Variation Phenotype References
4 c.220delG p.Val74TrpfsX40 Frameshift (compound
heterozygous with
p.Asn269LysfsX43)
Juvenile hemochromatosis 42
5 c.238T>C p.Cys80Arg Missense (compound
heterozygous with
p.Leu101Pro or p.Arg326X)
Juvenile hemochromatosis 43,44
6 c.239G>A p.Cys80Tyr Missense (compound
heterozygous with p.Gly320Val)
Juvenile hemochromatosis 34
7 c.253T>C p.Ser85Pro Missense (homozygous) Juvenile hemochromatosis 42
8 c.295G>A p.Gly99Arg Missense (homozygous or
compound heterozygous
with p.Leu101Pro)
Juvenile hemochromatosis 34,42
9 c.296G> T p.Gly99Val Missense Juvenile hemochromatosis 8
10 c.302T>C p.Leu101Pro Missense (homozygous or
compound heterozygous
with p.Cys80Arg or
p.Gly99Arg; heterozygous)
Juvenile hemochromatosis
Putative modifier in
p.Cys282Tyr HFE
homozygous when
heterozygous
42,43,45
11 c.314C>T p.Ser105Leu Missense (heterozygous) Putative modifier in
p.Cys282Tyr HFE
homozygous
45
12 c.346C>T p.Gln116X Nonsense (compound
heterozygous
with p.Gly320Val)
Juvenile hemochromatosis 46
13 c.356G> T p.Cys119Phe Missense (homozygous) Juvenile hemochromatosis 47
14 c.391_403del13 p.Arg131PhefsX115 Frameshift (homozygous) Juvenile hemochromatosis 42
15 c.404T>G p.Leu135Arg Missense (heterozygous) Putative modifier in
p.His63Asp
HFE homozygous
48
16 c.445delG p.Asp149ThrfsX97 Frameshift (homozygous) Juvenile hemochromatosis 42
17 c.494T>A p.Leu165X Nonsense (homozygous) Juvenile hemochromatosis 49
18 c.503C>A p.Ala168Asp Missense (homozygous) Juvenile hemochromatosis 42
19 c.509T>C p.Phe170Ser Missense (homozygous) Juvenile hemochromatosis 42
20 c.512G> T p.Gly171Val Missense (homozygous) Juvenile hemochromatosis 50
21 c.516C>G p.Asp172Glu Missense (compound
heterozygous with
p.Cys321ValfsX21)
Juvenile hemochromatosis 42
22 c.526C>T p.Arg176Cys Missense (homozygous
or compound
heterozygous
with p.Gly320Val)
Juvenile hemochromatosis 51,52
23 c.573G> T p.Trp191Cys Missense (homozygous) Juvenile hemochromatosis 42
24 c.575C>T p.Pro192Leu Missense (homozygous) Juvenile hemochromatosis 34
25 c.581T>C p.Leu194Pro Missense (homozygous) Juvenile hemochromatosis 34
26 c.588T>G p.Asn196Lys Missense (heterozygous) Putative modifier in
p.Cys282Tyr/p.His63Asp
HFE compound heterozygous
53
27 c.615C>G p.Ser205Arg Missense (compound
heterozygous with
p.Gly250Val)
Juvenile hemochromatosis 42
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Table 2 (Continued )
Nucleotide
Change
Amino Acid
Change Type of Variation Phenotype References
28 c.665T>A p.Ile222Asn Missense (compound
heterozygous with
p.Gly320Val)
Juvenile hemochromatosis 8,43
29 c.745G>C p.Asp249His Missense (homozygous) Hemochromatosis in middle age 54
30 c.749G>T p.Gly250Val Missense (compound
heterozygous with
p.Ser205Arg)
Juvenile hemochromatosis 42
31 c.806_807insA p.Asn269LysfsX43 Frameshift (compound
heterozygous with
p.Val74TrpfsX40)
Juvenile hemochromatosis 42
32 c.842T>C p.Ile281Thr Missense (homozygous or
compound heterozygous
with p.Cys321X)
Juvenile hemochromatosis 8,55
33 c.862C>T p.Arg288Trp Missense (homozygous) Juvenile hemochromatosis 42,56
34 c.904G>A p.Glu302Lys Missense (heterozygous) Putative modifier in
p.Cys282Tyr HFE
homozygous
45
35 c.934C>T p.Gln312X Nonsense (homozygous) Juvenile hemochromatosis 54,57
36 c.959G>T p.Gly320Val Missense (homozygous or
compound heterozygous;
heterozygous)
Juvenile hemochromatosis 8,34,42–44,46,
47,51,58–61
Putative modifier in
p.Cys282Tyr HFE
homozygous when
heterozygous
45
37 c.960_961insG p.Cys321ValfsX21 Frameshift (homozygous) Juvenile hemochromatosis 42
38 c.963C>G p.Cys321Trp Missense (compound
heterozygous with p.Gly320Val)
Juvenile hemochromatosis 43
39 c.963C>A p.Cys321X Nonsense (compound
heterozygous with p.Ile281Thr)
Juvenile hemochromatosis 55
40 c.976C>T p.Arg326X Nonsense (compound
heterozygous with
p.Cys80Arg or p.Gly320Val)
Juvenile hemochromatosis 8,44
41 c.982_985del4 p.Ser328AspfsX10 Frameshift (compound
heterozygous with p.Gly320Val)
Juvenile hemochromatosis 47
42 c.985C>T p.Arg329X Nonsense (homozygous) Juvenile hemochromatosis 62
43 c.1004G>A p.Arg335Gln Missense (heterozygous) Putative modifier in
p.Cys282Tyr HFE homozygous
45
44 c.1026delT p.Ala343ProfsX24 Frameshift (homozygous) Juvenile hemochromatosis 34
45 c.1080delC p.Cys361ValfsX6 Frameshift (homozygous) Juvenile hemochromatosis 8
46 c.1114A>G p.Asn372Asp Missense (heterozygous) Putative modifier in
p.Cys282Tyr HFE homozygous
45
47 c.1153C>T p.Arg385X Nonsense (homozygous) Juvenile hemochromatosis 42
HAMP (RefSeq NM_021175.2, NP_066998.1)
1 c.-153C>T Promoter mutation
(heterozygous)
Putative modifier in
p.Cys282Tyr
HFE homozygous
63
2 c.-25G>A Promoter mutation
(homozygous)
Juvenile hemochromatosis 64–66
3 c.95delG p.Gly32Aspfs Frameshift (homozygous) Juvenile hemochromatosis 7
4 c.126_127del2 p.Arg42Serfs Frameshift (homozygous) Juvenile hemochromatosis 34
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with slower progression of iron overload than in JHC.
Although relatively few cases have been documented,
the liver pathology is again described as strongly re-
sembling HFE-hereditary HC with early iron deposi-
tion in periportal hepatocytes (see Deugnier and
Turlin, this issue). Most demonstrate a milder degree
of iron overload than those with HFE-HC, although
there is progression to cirrhosis in some published
cases. The variability in clinical expressivity may also
depend on the underlying TFR2 defect that may have
different effects on hepcidin expression and the result-
ing iron-loading phenotype. The diagnosis is made by
clinical presentation, serum iron indices, and exclusion
of the HFE genotype. The leading diagnostic clue is
usually, as in the case of the other non-HFE HC
syndromes, unexplained hyperferritinemia (Fig. 1).
Treatment, as in the case of classic hereditary HC, is
by venesection.
Most reported cases of FPN-HC refer to patients
with clinical manifestations identical to HFE- (or
TFR2-) HC with high TF and SF levels, predominant
hepatic parenchymal iron overload, and cirrhosis and
organ failure in advanced cases.29–31,35 As in the other
forms of HC, phlebotomy appears to be well tolerated
and effective.
HJV-HC accounts for almost all cases of JHC,
the most severe form of human HC, known for
decades as a distinct clinicopathologic entity. The
first reports date back to the 1950s.75 Lamon76 first
reviewed all published cases and described the main
clinical features of JHC. The syndrome differs con-
siderably from HFE-HC with respect to age, an
almost equal ratio between sexes, greater frequency
of cardiac and endocrine disturbances.77–80 The pa-
tient usually presents in the second decade, typically
with hypogonadism that manifests as primary infer-
tility in the female. A dilated cardiomyopathy that
often becomes refractory to treatment is a common
complication; the untreated patient usually dies of
cardiac disease by the 30th year. The hepatic compli-
cations of iron overload in JHC may seem not as
common as in the case of adult forms of HC (HFE-,
TFR2, and FPN-HC), but this may be simply be-
cause the clinical picture is dominated by the endo-
crine and cardiac failure. In fact, the hepatic
pathology may be profound, with histologically diag-
nosed cirrhosis developing even at a young age in up
to 40% of patients. However, the clinical diagnosis of
JHC is often coincidental, relating to investigation of
endocrine or cardiac abnormalities including cardiac
Table 2 (Continued )
Nucleotide
Change
Amino Acid
Change Type of Variation Phenotype References
5 c.148_150þ1del4 p.Met50del Frameshift (heterozygous) Putative modifier in
p.Cys282Tyr HFE
heterozygous
67
6 c.166C>T p.Arg56X Nonsense (homozygous;
heterozygous)
Juvenile hemochromatosis
Putative
modifier in p.Cys282Tyr HFE
homozygous when
heterozygous
7,68
7 c.175C>G p.Arg59Gly Missense (heterozygous) Putative modifier in p.Cys282Tyr
HFE homozygous and
heterozygous
68
8 c.208T>C p.Cys70Arg Missense (homozygous) Juvenile hemochromatosis or
hemochromatosis
69,70
9 c.212G>A p.Gly71Asp Missense (heterozygous) Putative modifier in
p.Cys282Tyr HFE homozygous
67,68
10 c.233G>A p.Cys78Tyr Missense (homozygous) Juvenile hemochromatosis 71
Gene TFR2þHFE
1 HFE: c.187C>G/
c.845G>A
HFE: p.His63Asp/
p.Cys282Tyr
HFE missense and
TFR2 nonsense
Juvenile hemochromatosis 24
TFR2: c.949C>T TFR2: p.Gln317X (digenic inheritance:
HFE compound
heterozygous and
TFR2 homozygous)
TFR2, transferrin receptor-2; SLC40A1, ferroportin; HJV, hemojuvelin; HAMP, hepcidin.
*Reports of patients with a classic hemochromatosis phenotype but lacking confirmatory liver histopathology.
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shock. Glucose intolerance is manifest in almost two-
thirds of patients and there may be presentation due
to arthropathy or skin changes. Iron liver pathology in
JHC are similar to those of hereditary HC in that
there is progressive iron loading of parenchymal cells
with typical sparing of the reticuloendothelial system
(see Deugnier and Turlin, this issue). As in other
forms of HC, aggressive venesection remains the
cornerstone of therapy. Depending on the extent of
progression of the disease, there may be a place for
chelating therapy and cardiac transplant.78
Ferroportin Disease
In 1999, when only one HC gene (i.e., HFE) was
known, a non-HFE hereditary iron-overload condition
with typical reticuloendothelial iron deposits was de-
scribed in a large family from Italy.10 In the wake of the
discovery of ferroportin, genome-wide screening proce-
dures confirmed that the disease gene was SLC40A1,
coding for ferroportin, on chromosome 2q32.9 All pa-
tients were heterozygous for a c.230C—a substitution
resulting in the replacement of alanine 77 with aspartate.
This was subsequently referred to as ferroportin disease
(FD).72
EPIDEMIOLOGY
As opposed to HFE- and non-HFE-HC, the
pattern of inheritance of FD is autosomal dominant.
Therefore, either parent carries the pathogenic
mutation of FPN and presents with unexplained
hyperferritinemia. Numerous mutations of the FPN
Figure 1 In patients with unexplained hyperferritinemia, regardless of the level of serum iron, cofactors and comorbidities
associated with increased serum ferritin (SF) (e.g., chronic alcohol consumption, metabolic disturbances, obesity, inflammation,
etc.) should be considered first. In the absence of these comorbidities, or if the iron abnormalities persist after these conditions
have been effectively treated. If transferrin saturation (TS) is persistently elevated, HFE-hemochromatosis (HC) should be
excluded by genetic testing. If HFE test is not diagnostic, parenchymal iron overload must be confirmed, ideally by liver biopsy
(LB), before considering non-HFE-HC. Parenchymal iron overload in adults, in the absence of thalassemia intermedia/
nontransfused hereditary anemias with inefficient erythropoiesis or advanced cirrhosis, is typical of TFR2-hemochromatosis,
or more rarely, ferroportin-(FPN-) related forms. In young patients with severe cardiomyopathy and hypogonadism, juvenile HC
should be considered and hemojuvelin-(HJV-) and hepcidin-(HAMP-) gene sequencing performed. If available. In patients with
increased SF levels and normal-low TS, in the absence of common causes of hyperferritinemia (see above), the workup should
focus on documenting an iron-overload state by LB or magnetic resonance imaging (MRI). If so, depending on the pattern of iron
distribution (e.g., preferential Kupffer cells, iron overload) and/or accompanying symptoms (e.g., severe anemia and/or
neurologic disorders) ferroportin disease or other much rarer hereditary iron loading diseases can be considered (see text for
details). TS, transferrin saturation.
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gene have been identified so far in families with
primary hyperferritinemia, with divergent findings
with respect to the pattern of ferritin/transferrin
dissociation in probands of French-Canadian, Mela-
nesian, Thai, Asian, and European heritage
(Table 3).9,28,34,37,38,81–98 Yet, a few common FPN
mutations have been independently reported in differ-
ent countries (e.g., p.Val162del; p.Ala77Asp;
p.Gly80Ser) (Table 3).
Overall, these figures make ferroportin disease the
most common form of hereditary iron overload beyond
HFE-HC.
PATHOGENESIS
The pathogenesis is quite different from hereditary HC
and is discussed in this issue by De Domenico, Ward,
and Kaplan. As originally hypothesized,9 the disorder is
due to a loss of iron-export function of FPN: the
Table 3 Ferroportin Disease: Reported Mutations
SLC40A1 (RefSeq NM_014585.5, NP_055400.1)
Nucleotide
Change
Amino Acid
Change
Type of
Variation* Phenotype Reference
1 c.134C>A p.Ala45Glu Missense Ferroportin disease
y 98
2 c.206C>T p.Ala69Val Missense Ferroportin disease
y 98
3 c.212C>T p.Ser71Phe Missense Ferroportin disease
y 98
4 c.214G> T p.Val72Phe Missense Ferroportin disease 94
5 c.230C>A p.Ala77Asp Missense Ferroportin disease 9,89,99
6 c.238G>A p.Gly80Ser Missense Ferroportin disease 92,96,98,100,101
7 c.239G> T p.Gly80Val Missense Ferroportin disease 88
8 c.262A>G p.Arg88Gly Missense Ferroportin disease 27,98
9 c.263G>C p.Arg88Thr Missense Ferroportin disease 91
10 c.454A>T p.Ile152Phe Missense Ferroportin disease 93
11 c.469G>A p.Asp157Asn Missense Ferroportin disease 94
12 c.470A>C p.Asp157Ala Missense Ferroportin disease 97
13 c.470A>G p.Asp157Gly Missense Ferroportin disease 85,98
14 c.473G> T p.Trp158Leu Missense Ferroportin disease 98
15 c.474G> T p.Trp158Cys Missense Ferroportin disease 38
16 c.484_486del3 p.Val162del Deletion Ferroportin disease 81–84,87,98,
99,102,103
17 c.521A>T p.Asn174Ile Missense Ferroportin disease 100
18 c.532C>G p.Arg178Gly Missense Ferroportin disease 102
19 c.533G>A p.Arg178Gln Missense Ferroportin disease 27,98
20 c.539T>C p.Ile180Thr Missense Ferroportin disease 91
21 c.542A>T p.Asp181Val Missense Ferroportin disease 88,98
22 c.546G> T p.Gln182His Missense Ferroportin disease 85,98
23 c.553A>G p.Asn185Asp Missense Ferroportin disease 98,104
24 c.554A>C p.Asn185Thr Missense Ferroportin disease
y 98
25 c.610G>A p.Gly204Ser Missense Ferroportin disease
y 98
26 c.695C>A p.Ala232Asp Missense Ferroportin disease 105
27 c.698T>C p.Leu233Pro Missense Ferroportin disease 93,98
28 c.744G> T p.Gln248His Missense Ferroportin disease
y 106,107
29 c.800G>A p.Gly267Asp Missense Ferroportin disease 88
30 c.809A>T p.Asp270Val Missense Ferroportin disease 108
31 c.968G> T p.Gly323Val Missense Ferroportin disease 85
32 c.1111C> T p.Arg371Trp Missense Ferroportin disease
y 98
33 c.1112G>A p.Arg371Gln Missense Ferroportin disease
y 98
34 c.1402G>A p.Gly468Ser Missense Ferroportin disease
y 109
35 c.1466G>A p.Arg489Lys Missense Ferroportin disease 110
36 c.1467A>C p.Arg489Ser Missense Ferroportin disease 90
37 c.1468G>A p.Gly490Ser Missense Ferroportin disease 27,98
38 c.1469G>A p.Gly490Asp Missense Ferroportin disease 86
*All reported ferroportin mutations are at the heterozygous state, according to the autosomal dominant trait.y
Reported data do not allow to conclusively assign a classic ferroportin diseases phenotype.
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resultant reduction in iron efflux causes a bottleneck in
macrophages, which generate the largest iron flows,
resulting in iron accumulation in Kupffer cells (KC)
and macrophages with high SF levels and low to normal
TS until late in the disease when TS also rises. The
low-normal TS despite high SF is the biochemical
hallmark of the disease, and along with the early and
preferential accumulation of iron in hepatic KC (see
Deugnier and Turlin, this issue) is central in the
diagnostic workup of the disorder (Fig. 1). Although
KC iron load is an early feature of FD and essential in
the differential diagnosis with HFE-HC, discrete hep-
atocytic iron deposits are also appreciable in the classic
FD, due to defective FPN activity in hepatocytes, even
at early stages.10
CLINICAL ASPECTS
Clinical presentation appears heterogeneous, but
overall, expressivity is milder than classic HC and
the associated liver disease is usually not as severe.
Hypochromic anemia is common in young females,
and may require iron supplementation, which may
further exacerbate the iron overload. Although ven-
esection is again the cornerstone of therapy, it may
not be tolerated equally in all patients and low TS
with anemia may be rapidly established despite SF
still being elevated.72 If phlebotomy is discontinued,
there is a rapid rise in the ferritin level and both oral
chelation and erythropoietin may be of some benefit.
The disease must be suspected in any individual with
unexplained hyperferritinemia, and investigated with
serum iron studies and genetic testing, if available, of
the immediate family (Fig. 1). Abdominal magnetic
resonance imaging (MRI) is a useful noninvasive
diagnostic tool to categorize and diagnose the disor-
der, as it can differentiate patients with classic FD,
characterized by liver, spleen, and bone marrow iron
retention, from the rarer nonclassic form of FPN-
related iron load (i.e., FPN-HC), associated with liver
iron overload, but normal spleen and bone marrow
iron content.111
Aceruloplasminemia
This is an extremely rare autosomal recessive disease,
first reported by Miyajima,112 described mainly in
Japanese patients and due to loss of function muta-
tions in ceruloplasmin (CP) and resulting in iron
overload in the liver and pancreas and progressive
neurodegeneration.113–115 Ceruloplasmin is a copper-
containing ferroxidase synthesized by hepatocytes that
catalyzes the oxidation of ferrous to ferric iron,
necessary for the release of iron to plasma trans-
ferrin.116,117 This activity may involve the stabiliza-
tion of membrane FPN.118 Patients develop diabetes
mellitus, retinal degeneration, ataxia, and dementia
late in life.119 A mild-to-moderate degree of anemia
with low serum iron and elevated SF is a constant
feature and the pattern of hepatic iron overload is
reminiscent of hereditary HC, but fibrosis or cirrhosis
is uncommon. The disease should be suspected in
cases presenting with anemia, high SF, and neurologic
involvement. Brain MRI with typical iron accumula-
tion in basal ganglia and thalamus may help confirm
the diagnosis. Iron chelators have been used with
beneficial effects.120,121
Atransferrinemia/Hypotransferrinemia
An extremely rare autosomal recessive hereditary disor-
der, atransferrinemia, was first described in a young girl
with severe hypochromic anemia, and marked general-
ized iron overload122 it, has since been described in very
few families worldwide.122,124–128 Transferrin delivers
iron to the erythroid precursors and the defect leads to
decreased hemoglobin synthesis resulting in a severe
microcytic hypochromic anemia. However, this in turn
leads to increased intestinal absorption that, although
inefficiently handled in the plasma, is efficiently im-
ported by parenchymal cells leading to often severe
parenchymal iron overload at sites including the liver,
myocardium, pancreas, and thyroid. Clinical presenta-
tion and features include pallor and fatigue with high SF,
serum iron, and decreased total iron-binding capacity
(TIBC). Treatment may be relatively effective, at least in
some patients, via combined infusion of fresh frozen
plasma, and subsequent phlebotomy or chelation ther-
apy.
DMT-1 Deficiency
Divalent metal transporter 1 (DMT1) is the protein at
the apical membrane of the duodenal enterocyte that
transports iron (and other divalent ions) upon reduction
to its ferrous state by the brush border ferrireductase
DcytB.129 DMT1 also allows the iron exit from the
acidified endosomes. Autosomal recessive mutations of
DMT1 have been recently reported.130–135 All patients
with DMT1 deficiency present with severe hypochromic
microcytic anemia at birth, increased TS with normal
TIBC, and slightly elevated SF, increased soluble trans-
ferrin receptor. All reported cases except one,135 unlike
the DMT1 mutant animal models, present with marked
hepatic iron overload. Patients appear to respond to
erythropoietin.136,137
H-Ferritin-Related Iron Overload
Hyperferritinemia and concomitant hepatic iron over-
load have been described in four of seven members
of a Japanese family carrying a heterozygous single
point mutation (A49U) of the IRE motif in the
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50-untranslated region (50UTR) of H-ferritin mRNA
(þ 49A>T)138. No further cases have been reported
since the original series. However, an elegant animal
study has recently showed that mice with an intestinal
ferritin H gene deletion develop hemochromatosis,139
indicating that intestinal ferritin H is also required to
limit iron efflux from intestinal cells, and that ferritin
is an iron-loading gene, at least in mice.
Hereditary Iron-Loading Anemias with
Inefficient Erythropoiesis or Altered
Intracellular Iron Traffic
Within the spectrum of hereditary anemias, variable
iron overload in the liver may be identified not only
due to transfusional iron, but also to primary abnor-
malities of iron metabolism (see also, Deugnier and
Turlin, this issue). The thalassemias, due to inherited
defects of either the a or b globin chains of
hemoglobin, represent the most common single gene
inherited disorder in the world.140 Although trans-
fusions may largely account for the iron-overload states
found in these patients (see below), the characteristic
ineffective erythropoietic drive likely induces excess
iron absorption via inhibition of hepcidin synthesis
(see Babitt and Lin, this issue) and leads to hepatic
iron overload. This is especially evident in patients
with thalassemia intermedia who present marked pa-
renchymal iron overload that mimics HFE-HC (see
also, Deugnier and Turlin, this issue). Similar mech-
anistic phenomena may occur in the sideroblastic
hereditary (and acquired) anemias characterized by
anemia with ringed sideroblasts in the bone marrow
and iron overload.141
Liver disease, due to iron-driven oxidative
damage but also to concomitant viral hepatitis, is
common in b-thalassemia, the more severe and clin-
ically important hemoglobinopathy. Standard pegy-
lated interferon/ribavirin therapy can be successfully
used in these patients142: the aggravation of the
underlying anemic state due to the hemolytic activity
of ribavirin can be managed by using erythropoiesis-
stimulating agents and blood transfusions. Thalasse-
mic patients with chronic liver disease need close
hepatic ultrasound surveillance for hepatocellular car-
cinoma (HCC).
In X-linked sideroblastic anemia, due to muta-
tions of delta-aminolevulinic acid synthetase 2, the
primary pathogenic event is excessive deposition of
mitochondrial iron (Table 1). Seemingly, in Friedreich
ataxia,143 an autosomal recessive, degenerative disease
that involves the central and peripheral nervous systems
and the heart, a defect in iron-sulfur cluster assembly
interferes with iron export from mitochondria. These
conditions represent the paradigm of a new class of iron-
loading disorders due to iron mis-distribution within the
cell (Table 1), and seem to benefit from the use of iron
chelators.144
ACQUIRED DISORDERS
Enteral/Parenteral Iron Overload
Iron overload may arise from excessive iron introduction
through the enteral or parenteral route (Table 1). Usu-
ally, it is the long-term blood transfusion for hereditary
anemias or various causes of bone marrow failure (e.g.,
aplastic anemia, myelodysplastic syndrome, etc.), which
may cause a clinically apparent iron-loading disorder.
This may also be the case in transfusion-dependent
anemic patients with chronic kidney disease and long-
term dialysis. The iron excess, in all these cases, is
derived from senescent red blood cells and will thus
preferentially accumulate in KC and macrophages; it is
usually associated with some architectural disturbance in
the liver, whereas endocrine glands and the heart are the
preferential targets of toxicity and failure. Iron chelators
are the mainstay of treatment in posttransfusion iron
overload.145 The reporting of responses to chelation
therapies has typically focused on average changes in
serum ferritin in patient populations. This approach has
limitations. Changes in serum ferritin may not reflect
trends in iron balance equally in all patients or for all
chelation regimens and provide no useful information
about the proportion of responder patients. For example,
this gives insufficient information about iron trends in
tissues such as the heart. Recently, monitoring of iron
overload and response to therapy has advanced with the
increasing use of MRI techniques to estimate iron
balance (changes in liver iron concentration) and extra-
hepatic iron distribution (myocardial T2*).146 A patient’s
lack of a response may result from inadequate dosing,
high transfusion requirement, poor treatment adherence,
or unfavorable pharmacology of the chelation regime. In
fact, despite therapeutic improvements with the use of
new and potent iron chelators, it is still cardiac iron
overload that causes most deaths in posttransfusion iron-
loading anemias.145 The efficacy of iron chelation in
patients with chronic kidney disease is often complicated
by the presence of a chronic inflammatory state that leads
to iron sequestration in the reticuloendothelial system
and prevents iron redistribution.147
Chronic Liver Diseases
Common chronic liver diseases, including viral hepatitis,
alcoholic liver disease, nonalcoholic fatty liver disease,
and HCC, are often associated with varying degrees of
iron loading.148 This may be of low grade, but is some-
times sufficiently severe as to mistakenly identify heredi-
tary HC, although this is less of a problem after the
introduction of genotyping. Important questions still
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have to be answered, however. These include the rela-
tionship between iron and the primary disease as well as
its possible association with the various types of heredi-
tary HC. Recent advances in the understanding of the
iron regulatory genes and in particular hepcidin increas-
ingly support a direct relationship between disease pro-
gression and a pathogenic role for iron. Pathologic and
diagnostic aspects and the role of liver biopsy in hepatic
iron overload found in the course of various liver diseases
is discussed by Deugnier and Turlin (this issue).
MISCELLANEOUS DISORDERS
Several human diseases due to both hereditary (clearly
identified or suspected) and acquired disorders are char-
acterized by iron accumulation in the liver.
Porphyria Cutanea Tarda
Porphyria cutanea tarda (PCT), the most common
porphyria, is caused by a deficiency of uroporphyrinogen
decarboxylase activity (UROD).149 In the sporadic sub-
type (75% of cases), UROD activity is deficient only in
the liver, whereas in the familial subtype (25% of cases),
an autosomal dominant disorder at early-onset disorder
affecting both sexes, the defect leads to a constitutive
50% UROD deficiency also in the erythrocytes.150
Porphyria cutanea tarda is a complex disease in which
both a multigenic predisposition and environmental risk
factors are needed for clinical expressivity. The risk
factors that contribute to inactivation or inhibition of
this enzyme are mainly alcohol abuse, estrogens, hep-
atitis C, and to a lesser extent, HIV infections and
inheritance of one or more HFE genotypes.151–153
Symptoms develop when residual, hepatic UROD de-
creases below a threshold of 25%. Clinical features
include photosensitive skin lesions, hepatic accumula-
tion and urinary excretion of uroporphyrins, altered iron
indices, and hepatic iron overload. Iron removal by
phlebotomy is part of the current therapeutic strategy
in PCT: It improves the clinical outcome and biochem-
ical signs of the disease.154
African Siderosis
African iron overload, formerly called Bantu siderosis,155
is still an important pathology in rural society where up
to 15% of adult males may be affected. It was originally
described by Strachan in individuals from several parts of
southern and central Africa in the 1920s.156 Originally,
iron overload was attributed to consumption of food, or
more significantly to large quantities of traditional beer
prepared in iron pots.157 Later, a genetic modifier was
postulated,158 and a polymorphism of the ferroportin
gene (p.Gln248His) restricted to Africans and African
Americans has been considered a candidate modi-
fier,106,107 but no conclusive evidence has been provided
so far. Regardless of a predisposing genetic trait, alco-
holic beverages are a main factor leading to iron overload
and liver disease in southern Africa’s rural adult pop-
ulation. They may develop cirrhosis and HCC and liver
iron concentration may reach the level found in HFE-
HC and beyond.159
Alloimmune (Neonatal) Hemochromatosis
Neonatal hemochromatosis (NH) is a severe neonatal
disease characterized by stillbirth or neonatal liver failure
in the antenatal or early neonatal period, usually within a
period of hours to days postdelivery.160 Intrauterine
growth retardation, and associated placental edema and
either oligohydramnios or polyhydramnios are common.
The prevailing presentation is jaundice with coagulop-
athy, hypoglycemia, and hypoalbuminemia and high SF.
Thus, diagnosis is made after exclusion of other causes of
liver failure and may be confirmed by (1) salivary gland
biopsy, which demonstrates excess iron; and (2) MRI,
which typically shows iron deposition in liver, pancreas,
and heart, but with sparing of the spleen.161 Various
theories have been put forth to explain the etiology of
NH, including fetal liver injury causing abnormalities of
iron handling, or alternatively, abnormalities of iron
handling by the maternofetal unit, with the possibility
existing that they are not mutually exclusive.160 There is
a high rate of recurrence if a mother has a previous
pregnancy complicated by NH; occasionally, it has been
also documented in consanguineous families, which has
been considered support that NH is a genetic disease.
However, a candidate gene has not yet being identified.
On the contrary, recently, an alloimmune mechanism for
the disease has been postulated.161 Neonatal hemochro-
matosis may represent the phenotypic expression of
gestational alloimmune foetal liver disease induced by
the placental passage of specific reactive immunoglobu-
lin G and involving the activation of fetal complement
by the classical pathway leading to the formation of
membrane attack complex as the effector of cell injury.
Recently, Pan et al162 found that the percentage of
hepatocytes containing antiterminal complement cas-
cade neoantigens involved in membrane attack complex
formation in NH was much greater than that in non-
NH liver disease. In this vein, high-dose intravenous
immunoglobulin therapy (IVIG) to the mother appears
to significantly increase survival of newborns163; high-
dose IVIG, with or without exchange transfusions, to
newborns achieved 75% good outcome compared with
17% in historical controls not treated with IVIG.164 The
prognosis of NH is extremely poor. Antioxidant therapy
and chelation appear to be of limited value, and although
liver transplantation has been identified as a viable
therapeutic option, there may be reaccumulation of
hepatic iron.165
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ABBREVIATIONS
CP ceruloplasmin
DMTI divalent metal transporter-1
FD ferroportin disease
FPN ferroportin
HAMP hepcidin
HC hemochromatosis
HCC hepatocellular carcinoma
HJV hemojuvelin
IVIG intravenous immunoglobulin
JHC juvenile hemochromatosis
KC Kupffer cells
MRI magnetic resonance imaging
NH neonatal hemochromatosis
PCT porphyria cutanea tarda
SF serum ferritin
TFR2 transferrin receptor 2
TIBC total iron binding capacity
TS transferrin saturation
UROD uroporphyrinogen decarboxylase
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